News On Japan

Breakthrough on Carbon Monoxide Poisoning Treatment?

KYOTO, Feb 26 (News On Japan) - Isn't it beautiful? In a flask containing a substance with a deep purple hue, Professor Akira Kitagishi from Doshisha University is conducting an experiment that may create a groundbreaking therapeutic drug.

'I get fired up when making things. Whether it's creating something new or making a lot of things, it's simply about the act of creation, which is fascinating,' said a student, expressing admiration for Professor Kitagishi.

Professor Kitagishi may have discovered a substance that could significantly advance emergency medical care. It's called HemoCD. It has the property of strongly adsorbing toxic gases like carbon monoxide and cyanide, so when ingested, it adsorbs the toxic gas components and excretes them all in the urine. This property makes it usable as an antidote for gas poisoning.

In a recent case, six people were transported to this hospital in a state of cardiac arrest, and four of them died, apparently from carbon monoxide poisoning. The most common cause of death in building fires is carbon monoxide poisoning. In the arson murder case at Kitashinchi Building in December 2021, all 26 people who died were due to carbon monoxide poisoning. Professor Kitagishi watched the news of this incident with mixed feelings. 'I felt really frustrated at that time. So, yes, people inhale oxygen through breathing, and blood carries oxygen throughout the body. When you get carbon monoxide poisoning, you can't absorb oxygen into your body, and if the concentration in your blood is high, you can die in a few minutes to tens of minutes. But in today's medical care, there is no treatment. That's why it's a race against time to see how quickly you can respond.'

HemoCD, developed by Professor Kitagishi, is expected to be effective in treating carbon monoxide poisoning. It is named for its function similar to hemoglobin in the blood. The mechanism of HemoCD is as follows: Normally, hemoglobin in the blood carries oxygen throughout the body. However, carbon monoxide binds to hemoglobin more easily than oxygen, preventing oxygen from being transported in the body. HemoCD has a property that readily binds to carbon monoxide and removes it from the body, excreting it as urine.

The efficacy of HemoCD has been demonstrated in experiments. Mice that were poisoned with carbon monoxide were given HemoCD, and although they were initially unable to move and were lethargic, after about 30 minutes, the mice began to move. Furthermore, about two hours later, all the HemoCD administered to the mice was excreted in their urine, showing that no chemicals remained in their bodies. This indicates that HemoCD could save many lives at the scene of a fire.

HemoCD actually originated from a failed experiment that Professor Kitagishi had been working on. Professor Kitagishi, who was conducting research to create artificial blood, found that when administered to mice, it was immediately excreted in urine, which was a negative result. 'When you want to use it as artificial blood and it all comes out in urine, it's just negative information, and it was very disappointing.' However, his years of experience and keen observation did not let him overlook a slight change. 'When I was staring blankly, I noticed that it was a bit red. It was something I always knew, but it looked red. So, I thought I'd look into it a bit, and when I did, I found that it was binding with carbon monoxide.'"

Source: MBS NEWS

News On Japan
POPULAR NEWS

The entire population of pandas at Adventure World in Shirahama, Wakayama Prefecture, is being returned to China, delivering a major blow to both the mayor and residents. The emotional and economic impact is significant.

The rules surrounding benefits for parents on childcare leave were tightened in April due to concerns over the practice known as 'aiming to miss nursery placement.'

The "phantom bridge," a Hokkaido heritage site in the Tokachi region known for appearing and disappearing with the seasons, has begun drawing visitors again in 2025 as its elusive form grows increasingly fragile.

Kazuki Tomono of Daiichi Juken Group performed his new short program for the upcoming season targeting the Milan-Cortina Winter Olympics during the Prince Ice World show held in Yokohama on April 26th.

Japan's prison system is undergoing a major shift as it prepares to introduce "confinement punishment," moving away from traditional penal servitude that emphasized punishment toward a new focus on rehabilitation.

MEDIA CHANNELS
         

MORE Sci-Tech NEWS

Vegetables that were destined for disposal are being given a new purpose as crayons that retain their natural colors and even a faint trace of their original scent.

One of the main attractions at the Osaka-Kansai Expo, the "flying car," experienced an unexpected malfunction, raising concerns about safety and delaying its return to operation.

What does it feel like to have Restless Legs Syndrome? To me, it’s like being buried in sand, with a deep heavy ache, and trying to resisting the urge to move making it even more unbearable.

Organic fluorine compounds known as PFAS—suspected to be harmful to human health—have been detected at concentrations exceeding the national provisional target in rivers and groundwater at 242 sites across 22 prefectures, according to a government survey.

Kyoto University and its research team have revealed that several former employees of Daikin Industries developed lung diseases, potentially linked to exposure to PFAS (per- and polyfluoroalkyl substances), a group of chemical compounds used in industrial manufacturing.

Amazon held a product briefing for its security brand "Ring" in Fukuoka City on April 21st, aiming to boost recognition in Fukuoka Prefecture, where the population continues to grow.

Japanese astronaut Takuya Onishi has been appointed commander of the International Space Station (ISS), becoming the third Japanese to assume the role.

A new treatment for Parkinson's disease using iPS cells developed by Kyoto University has shown a certain level of effectiveness in clinical trials.